BRPI0607096A2 - inibição mediada por rnai de alvos de hipertensão ocular - Google Patents

inibição mediada por rnai de alvos de hipertensão ocular

Info

Publication number
BRPI0607096A2
BRPI0607096A2 BRPI0607096-5A BRPI0607096A BRPI0607096A2 BR PI0607096 A2 BRPI0607096 A2 BR PI0607096A2 BR PI0607096 A BRPI0607096 A BR PI0607096A BR PI0607096 A2 BRPI0607096 A2 BR PI0607096A2
Authority
BR
Brazil
Prior art keywords
ocular hypertension
targets
mediated inhibition
ocular
mrna
Prior art date
Application number
BRPI0607096-5A
Other languages
English (en)
Inventor
Allan R Shepard
Abbot F Clark
Jon E Chatterton
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0607096A2 publication Critical patent/BRPI0607096A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03009—Na+/K+-exchanging ATPase (3.6.3.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INIBIçãO MEDIADA POR RNAi DE ALVOS DE HIPERTENSãO OCULAR. Inteferência de RNA é provido para inibição de expressão de mRNA alvo de hipertensão ocular para diminuição da pressão intraocular elevada em pacientes com glaucoma de ângulo aberto ou hipertensão ocular. Alvos de hipetensão ocular incluem anidrase carbónica II, IV e XII; receptores adrenérgico 1 e 2; acetilcolinesterase; Na^ +^/K^ +^-ATPase; e cotransportador de Na-K-2C1. Hipertensão ocular é tratada por administração de RNAs de interferência da presente invenção.
BRPI0607096-5A 2005-02-01 2006-02-01 inibição mediada por rnai de alvos de hipertensão ocular BRPI0607096A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64892605P 2005-02-01 2005-02-01
US75336405P 2005-12-22 2005-12-22
PCT/US2006/004018 WO2006084217A2 (en) 2005-02-01 2006-02-01 Rnai-mediated inhibition of ocular hypertension targets

Publications (1)

Publication Number Publication Date
BRPI0607096A2 true BRPI0607096A2 (pt) 2009-08-04

Family

ID=36587258

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0607096-5A BRPI0607096A2 (pt) 2005-02-01 2006-02-01 inibição mediada por rnai de alvos de hipertensão ocular
BRPI0606979-7A BRPI0606979A2 (pt) 2005-02-01 2006-02-01 inibicão mediada por rnai de marcações oculares

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0606979-7A BRPI0606979A2 (pt) 2005-02-01 2006-02-01 inibicão mediada por rnai de marcações oculares

Country Status (14)

Country Link
US (4) US20060172963A1 (pt)
EP (2) EP1848803A2 (pt)
JP (2) JP2008528637A (pt)
KR (2) KR20070099673A (pt)
AR (2) AR052103A1 (pt)
AU (2) AU2006210451B2 (pt)
BR (2) BRPI0607096A2 (pt)
CA (2) CA2595678A1 (pt)
MX (2) MX2007009194A (pt)
RU (2) RU2007132874A (pt)
SA (1) SA06260487B1 (pt)
TW (2) TW200639252A (pt)
UY (2) UY29348A1 (pt)
WO (2) WO2006084217A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033977T2 (en) 2004-08-23 2018-02-28 Sylentis Sau Treatment of eye disorders with siRNAs characterized by increased intraocular pressure
WO2006099353A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
GB0505081D0 (en) * 2005-03-14 2005-04-20 Genomica Sau Downregulation of interleukin-12 expression by means of rnai technology
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
WO2007079128A1 (en) * 2005-12-30 2007-07-12 Ventana Medical Systems, Inc. Na+, k+-atpase expression in cervical dysplasia and cancer
KR20090042297A (ko) * 2006-08-24 2009-04-29 알콘 리서치, 리미티드 ＩＯＰ―관련 증상을 치료하기 위한 그렘린의 ＲＮＡｉ 매개 억제
WO2008092142A2 (en) * 2007-01-26 2008-07-31 Alcon Research, Ltd. Rnai-mediated inhibition of aquaporin 1 for treatment of ocular neovascularization
US20100292301A1 (en) * 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
CA2694091A1 (en) * 2007-10-01 2009-04-09 Alcon Research, Ltd. Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
RU2487716C2 (ru) * 2007-10-03 2013-07-20 Кварк Фармасьютикалс, Инк. Новые структуры малых интерферирующих рнк (sirna)
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
AR069328A1 (es) 2007-11-15 2010-01-13 Alcon Mfg Ltd Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
TW200932274A (en) * 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
EP2242854A4 (en) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc COMPOUNDS AND USES THEREOF
CA2962219C (en) * 2008-10-22 2020-08-25 Quark Pharmaceuticals, Inc. Methods for treating eye disorders
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
WO2013103467A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
AU2012389270B2 (en) 2012-09-05 2018-11-08 Sylentis S.A.U. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN109414414A (zh) 2016-03-16 2019-03-01 戴维·格拉德斯通研究所 用于治疗肥胖症和/或糖尿病以及用于鉴定候选治疗剂的方法和组合物
EP3388520A1 (en) * 2017-04-11 2018-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof
CN109557309B (zh) * 2018-12-04 2021-09-10 九江学院附属医院 碳酸酐酶-2作为检测标记物在肾结石诊断方面的应用
KR102414025B1 (ko) * 2019-06-27 2022-06-29 전북대학교 산학협력단 신규한 에이디피-라이보실 사이클라아제 및 이의 저해제
KR20240014109A (ko) * 2021-05-27 2024-01-31 알닐람 파마슈티칼스 인코포레이티드 탄산 무수화효소 2 발현을 침묵화하기 위한 조성물 및 방법
EP4536197A1 (en) 2022-06-07 2025-04-16 Generation Bio Co. Lipid nanoparticle compositions and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2361201A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20050112118A1 (en) * 1999-12-02 2005-05-26 Myriad Genetics, Incorporated Compositions and methods for treating inflammatory disorders
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
ES2336887T5 (es) * 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
IL154129A0 (en) * 2000-07-28 2003-07-31 Compugen Inc Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
ATE526041T1 (de) * 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
US20060088537A1 (en) * 2002-04-11 2006-04-27 Terrett Jonathan A Protein involved in cancer
EP1495120B1 (en) * 2002-04-18 2012-10-10 Acuity Pharmaceuticals, Inc Means and methods for the specific modulation of target genes in the eye
US8137910B2 (en) * 2002-05-03 2012-03-20 Duke University Method of regulating gene expression
AU2003261449A1 (en) * 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
AU2003278725A1 (en) * 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
WO2004022782A2 (en) 2002-09-04 2004-03-18 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for tissue specific or inducible inhibition of gene expression
JP2005537790A (ja) 2002-09-05 2005-12-15 ガーバン インスティテュート オブ メディカル リサーチ 新規診断および治療方法およびそのための試薬類
NZ540779A (en) 2002-11-01 2008-05-30 Univ Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
JP2006519594A (ja) * 2003-02-11 2006-08-31 イミューソル インコーポレイテッド 所定のタンパク質ファミリー用に最適化したｓｉＲＮＡライブラリー
US20050203043A1 (en) * 2004-01-23 2005-09-15 Dharmacon, Inc. Identification of toxic nucleotide sequences
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
EP1791567B1 (en) * 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
HUE033977T2 (en) * 2004-08-23 2018-02-28 Sylentis Sau Treatment of eye disorders with siRNAs characterized by increased intraocular pressure

Also Published As

Publication number Publication date
SA06260487B1 (ar) 2011-02-23
AR052102A1 (es) 2007-02-28
UY29349A1 (es) 2006-05-31
AU2006210451B2 (en) 2011-09-22
WO2006083945A3 (en) 2007-08-23
US20060172963A1 (en) 2006-08-03
AU2006210451A1 (en) 2006-08-10
MX2007009194A (es) 2007-09-14
US20110124708A1 (en) 2011-05-26
KR20070099673A (ko) 2007-10-09
AU2006210846A1 (en) 2006-08-10
US20090326044A1 (en) 2009-12-31
WO2006084217A3 (en) 2007-09-13
US20060172965A1 (en) 2006-08-03
US7592324B2 (en) 2009-09-22
WO2006083945A2 (en) 2006-08-10
TW200639252A (en) 2006-11-16
TW200639253A (en) 2006-11-16
CA2595678A1 (en) 2006-08-10
WO2006084217A2 (en) 2006-08-10
EP1848803A2 (en) 2007-10-31
MX2007009200A (es) 2007-09-14
JP2008528637A (ja) 2008-07-31
RU2007132848A (ru) 2009-03-10
BRPI0606979A2 (pt) 2009-07-28
KR20070099048A (ko) 2007-10-08
EP1846557A2 (en) 2007-10-24
JP2008528632A (ja) 2008-07-31
UY29348A1 (es) 2006-05-31
RU2007132874A (ru) 2009-03-10
WO2006083945A8 (en) 2007-10-11
AR052103A1 (es) 2007-02-28
CA2595790A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
BRPI0607096A2 (pt) inibição mediada por rnai de alvos de hipertensão ocular
MX2009001896A (es) Inhibicion medida por arn-i de gremlin para el tratamiento de condiciones relacionadas con iop.
TW200731979A (en) RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders
MX2009005993A (es) Tratamiento para ojo seco.
AR074525A1 (es) Cabezal de masaje y aparato masajeador que emplea dicho cabezal
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BRPI0607447A2 (pt) solução oftálmica de bimatoprost aprimorada
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
MX2007010608A (es) Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma.
BRPI0406880A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de inibidores de anidrase carbÈnicos
MX2009005644A (es) Gel util para el suministro de farmacos oftalmicos.
AR056852A1 (es) INHIBICIoN DE HIF1A INTERMEDIADO POR RNAI PARA EL TRATAMIENTO DE ANGIOGENESIS OCULAR
WO2008052081A3 (en) Photochemical therapy to affect mechanical and/or chemical properties of body tissue
GT200700064A (es) Agonistas de ep2
BRPI0710959A2 (pt) Uso de uma proteína anti-secretória e peptídeo
WO2008067382A3 (en) Rnai-mediated inhibition of aquaporin 4 for treatment of iop-related conditions
BR112013005224A2 (pt) "agonistas de adenosina a1 para o tratamento de glaucoma e hipertensão ocular".
AR064015A1 (es) Inhibicion mediada por arni de acuaporina 1 para tratamiento de afecciones relacionadas con pio
WO2009020848A3 (en) RNAI-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
WO2012024419A3 (en) Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
Arutyunyan et al. The hypotensive effect of Dorzopt in the treatment of postoperative eye hypertension in patients with cataract and primary open angle glaucoma
ZA200807828B (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
CY1118767T1 (el) Πεπτιδια που αναστελλουν την καλλικρεϊνη του πλασματος για χρηση στη θεραπεια οφθαλμικων διαταραχων
WO2008075148A3 (en) Tricyclic inhibitors of carbonic anhydrase
BRPI0419257A (pt) processo para preparar cloridrato de 5,6-diidro-4-(s)-(ettilamino)-6-(s)-metil-4h-tieno{2,3b}tio pirano-2-sulfonamida-7,7-dióxido

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI